Flynn: AIDS Clinical Trials

The St. Jude Children's Research Hospital HIV/AIDS clinical program began in 1987. The main objective is to find a cure for pediatric AIDS through protocol-driven clinical investigation. The institutional program was enhanced by the establishment of a unit of the NIAID Pediatric AIDS Clinical Trials Group (PACTG, now IMPAACT) in 1992, the Reaching for Excellence in Adolescent Care and Health (REACH) program of NICHD in 1997-2001, the Adolescent Trials Group in 2006, and the Pediatric HIV/AIDS Cohort Study in 2007.  The protocols available for patients with HIV/AIDS include primary therapy protocols for both treatment-naive and treatment-experienced patients, behavioral studies of infected children and adolescents, and long term follow up studies of infected and affected infants.  Investigators at St. Jude work closely with pharmaceutical companies in developing new therapies for HIV infection. Perinatal intervention protocols also play a major role. Through clinical research, current maternal-to-infant transmission rates are as low as 2 percent.  A major focus for our program is adolescent HIV infection.  Nationally, 25-50 percent of new HIV infection occurs in teens and young adults under the age of 25.  Over the next five years, we anticipate continued involvement in clinical trials through participation in cooperative groups, through collaborations with pharmaceutical companies, and through locally developed protocols. These trials include the following: